TrialPath
Recruiting

[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)

NCT07723651 · Washington University School of Medicine
In plain English

Click the button to translate this study into plain language — what it is, who qualifies, and what participation looks like.

Official title
Integration of FTT-PET and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC)
About this study
This multicenter center, open-label, baseline-controlled diagnostic imaging study designed to assess the use of Fluorthanatrace-Positron Emission tomography (FTT-PET) as a PARP inhibitor (PARPi) therapy predictive imaging biomarker and the use of EnhanceAR-Seq (ctDNA) in predicting response to therapy and to identify genomic alterations associated with resistance. Furthermore, to correlate changes in ctDNA and imaging (FTT-PET and standard of care imaging) to understand the dynamics of tumor response.
Eligibility criteria
Inclusion Criteria: * Adult male patients 18 years of age or older * mCRPC with confirmed germline or somatic HRR (such as ATM, ATR, BRCA1, BRCA2, CDK12, CHEK2, FANCA, MLH1, MRE11A, NBN, PALB2, or RAD51C for Talazoparib/enzalutamide and ATMm, BRCA1m, BRCA2m, BARD1m, BRIP1m, CDK12m, CHEK1m, CHEK2m, FANCLm, PALB2m, RAD51Bm, RAD51Cm, RAD51Dm, RAD54Lm; gBRCA1m, gBRCA2m; ATMm, BRCA1m, BRCA2m for Olaparib +/- abiraterone) mutations who are scheduled for SOC PARPi therapy. * Lesion size of at least 1.0 cm in longest dimension by imaging. If non-measurable, lesion needs to be clearly detected on other imaging studies such as bone scintigraphy, FDG-PET, PSMA-PET or MRI. * On continuous androgen deprivation therapy (ADT) with appropriately suppressed castrate testosterone levels of \< 50 ng/dL, or prior bilateral orchiectomy. * Serum PSA of 2 ng/mL or greater. * Eastern Cooperative Oncology Group (ECOG) performance status of 0-2. * Able to give informed consent Exclusion Criteria: * Receipt of prior PARP inhibitor therapy in any disease setting. * Patients with other invasive malignancies, with the exception of non-melanoma skin cancer, who had (or have) any evidence of the other cancer that is active at the time of enrollment. * Unable to tolerate approximately 30 min (total time) of PET/CT imaging.
Study design
Enrollment target: 75 participants
Allocation: na
Masking: none
Age groups: adult, older_adult
Timeline
Starts: 2026-11-30
Estimated completion: 2032-05-31
Last updated: 2026-11-20
Interventions
Drug: 1-(4-(2-Fluoroethoxy)phenyl)-8,9-dihiydro-2,7,9a-triazabenzo[cd]azulen-6(7H)-oneDevice: FTT-PET/CTDiagnostic Test: EnhanceAR-Seq
Primary outcomes
  • • Prediction performance of FTT-PET as measured by concordance index (C-index) (At baseline prior to PARPi therapy and post cycle 1 (estimated total time 28 days))
  • • Prediction performance of FTT-PET as measured by area under the receiver operating characteristic (ROC) curve (At baseline prior to PARPi therapy and post cycle 1 (estimated total time 28 days))
  • • Prediction performance of EnhanceAR-Seq ctDNAas measured by concordance index (C-index) (At baseline prior to PARPi therapy, post cycle 1 (cycle is an estimated 28 days), 12 weeks after start of PARPi therapy, and at progression if applicable (estimated total time 6 months))
Sponsor
Washington University School of Medicine · other
With: National Cancer Institute (NCI)
Contacts & investigators
ContactFarrokh Dehdashti, MD · contact · dehdashtif@wustl.edu · 314-362-1474
InvestigatorFarrokh Dehdashti, MD · principal_investigator, Washington University School of Medicine
All locations (3)
Washington University School of MedicineRecruiting
St Louis, Missouri, United States
University of Pennsylvania Abramson Cancer CenterNot Yet Recruiting
Philadelphia, Pennsylvania, United States
University of Texas MD Anderson Cancer CenterNot Yet Recruiting
Houston, Texas, United States
[18F]Fluorthanatrace - Positron Emission Tomography (FTT-PET) and ctDNA to Predict Response to PARP Inhibitor Therapy in Metastatic Prostate Cancer (mPC) · TrialPath